Vertex Forecasts 2026 Sales Growth Despite Q4 EPS Miss and Slow New Drug Uptake
Vertex Pharmaceuticals’ Q4 revenue rose on stronger cystic fibrosis franchise sales, led by Trikafta/Kaftrio and Alyftrek, despite earnings per share missing estimates. Uptake of new therapies Journavx and Casgevy lagged expectations, but management forecasts significant 2026 sales growth and advances five late-stage pipeline programs, including kidney disease candidate povetacicept.
1. Q4 Performance Highlights
Vertex posted quarterly sales above forecasts while non-GAAP earnings per share missed consensus, as robust cystic fibrosis franchise revenue was offset by slower uptake of newly launched therapies and higher operating costs.
2. Cystic Fibrosis Franchise Growth
Sales of Trikafta/Kaftrio and Alyftrek powered strong growth in the CF franchise, contributing to a 22.5% share price outperformance against the biomedical and genetics industry over the past six months.
3. New Therapy Uptake and Outlook
Journavx and Casgevy have experienced slower-than-expected market penetration since launch, leading management to project significant acceleration in combined sales for these assets in 2026.
4. Pipeline Advancement and Risks
Vertex is advancing five pivotal late-stage programs, including kidney disease candidate povetacicept, but remains heavily dependent on its CF franchise and faces concerns after a recent setback in its pain treatment program.